RT Journal Article
T1 Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.
A1 Jager, Kitty J
A1 Kramer, Anneke
A1 Chesnaye, Nicholas C
A1 Couchoud, Cécile
A1 Sánchez-Álvarez, J Emilio
A1 Garneata, Liliana
A1 Collart, Fréderic
A1 Hemmelder, Marc H
A1 Ambühl, Patrice
A1 Kerschbaum, Julia
A1 Legeai, Camille
A1 Del Pino Y Pino, María Dolores
A1 Mircescu, Gabriel
A1 Mazzoleni, Lionel
A1 Hoekstra, Tiny
A1 Winzeler, Rebecca
A1 Mayer, Gert
A1 Stel, Vianda S
A1 Wanner, Christoph
A1 Zoccali, Carmine
A1 Massy, Ziad A
K1 COVID-19
K1 attributable mortality
K1 dialysis
K1 kidney replacement therapy
K1 registries
K1 transplantation
AB The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk with the use of ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe from February 1, 2020, to April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from 7 European countries encompassing 4298 patients. COVID-19-attributable mortality was calculated using propensity score-matched historic control data and after 28 days of follow-up was 20.0% (95% confidence interval 18.7%-21.4%) in 3285 patients receiving dialysis and 19.9% (17.5%-22.5%) in 1013 recipients of a transplant. We identified differences in COVID-19 mortality across countries, and an increased mortality risk in older patients receiving kidney replacement therapy and male patients receiving dialysis. In recipients of kidney transplants ≥75 years of age, 44.3% (35.7%-53.9%) did not survive COVID-19. Mortality risk was 1.28 (1.02-1.60) times higher in transplant recipients compared with matched dialysis patients. Thus, the pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy, a highly vulnerable population due to underlying chronic kidney disease and a high prevalence of multimorbidity.
YR 2020
FD 2020-10-15
LK http://hdl.handle.net/10668/16321
UL http://hdl.handle.net/10668/16321
LA en
DS RISalud
RD Apr 10, 2025